Prosecution Insights
Last updated: April 19, 2026
Application No. 18/374,859

NAIL POLISH TOPCOAT COMPOSITION

Non-Final OA §103
Filed
Sep 29, 2023
Examiner
BABSON, NICOLE PLOURDE
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
3y 8m
To Grant
78%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
238 granted / 516 resolved
-13.9% vs TC avg
Strong +32% interview lift
Without
With
+31.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
63 currently pending
Career history
579
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
52.4%
+12.4% vs TC avg
§102
8.6%
-31.4% vs TC avg
§112
22.1%
-17.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 516 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-20 are pending. Election/Restrictions Applicant’s election without traverse of the invention of Group I, claims 1-11, drawn to a composition in the reply filed on 12/12/25 is acknowledged. Claims 12-20 are withdrawn as being drawn to a nonelected invention. Claims 1-11 are under consideration. Information Disclosure Statement Acknowledgement is made of Applicant’s information disclosure statements (IDS) submitted on 3/8/24 and 8/9/24. The submissions are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. Two identical IDS were submitted on 3/8/24, therefore only one has been signed and considered. Drawings The drawings are objected to because there is only one figure and the drawing refers to it as Figure 1. However, 37 CFR 1.84(u)(1) indicates when there is only one drawing, it must not be numbered and the abbreviation FIG must not appear. Therefore, the figure must be referred to as The Figure. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Specification The disclosure is objected to because of the following informalities: paragraph [0014] of the specification refers to Figure 1 but should state The Figure as there is only one figure. Appropriate correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-11 are rejected under 35 U.S.C. 103 as being unpatentable over Rughani et al. (US 2022/0257493). Rughani et al. teach cosmetic compositions for treating nails including a water-insoluble cellulose polymer, one or more additional film-formers, plasticizer, and a urea compound (e.g. abstract). Rughani et al. teach compositions comprising: - a solvent system comprising ethyl and butyl acetates (i.e. volatile acetates) (e.g. paragraph 0056; Claim 5; Table 1); - nitrocellulose (e.g. paragraph 0031; Claim 4; Table 1); - one or more additional film-formers (e.g. Claim 1; Table 1) comprising a silicone organic hybrid polymer comprising Crotonic Acid/Vinyl C8-12 Isoalkyl Esters/VA/Bis-Vinyldimethicone Crosspolymer (e.g. paragraph 0045); and an alkyd resin comprising phthalic anhydride/glycerol/glycidyl decanoate copolymer (e.g. paragraph 0046). Regarding Claims 1-3, 5 and 10, while there is not a single example comprising each of the claimed components, the ingredients are included among a short list of preferred ingredients. It would have been obvious to one of ordinary skill in the art at the time of the instant invention to combine the elements as claimed by known methods with no change in their respective functions, and the combination yielding nothing more than predictable results. Regarding Claim 4, Rughani et al. do not teach the inclusion of any phenyl moieties (i.e. entre disclosure). Regarding Claim 6, Rughani et al. teach 1-20 wt% of one or more additional film-formers (e.g. paragraph 0047) including a silicone organic hybrid polymer comprising Crotonic Acid/Vinyl C8-12 Isoalkyl Esters/VA/Bis-Vinyldimethicone Crosspolymer (e.g. paragraph 0045), which overlaps with the claimed ranges. In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) (MPEP 2144.05.I). Regarding Claim 7, Rughani et al. teach 1-20 wt% of one or more additional film-formers (e.g. paragraph 0047) including an alkyd resin comprising phthalic anhydride/glycerol/glycidyl decanoate copolymer (e.g. paragraph 0046), which overlaps with the claimed ranges. In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) (MPEP 2144.05.I). Regarding Claim 8, Rughani et al. teach that the composition may include a colorant (i.e. the composition may also be free of a colorant) (e.g. paragraph 0062). In addition, Rughani et al. teach that if included, the colorant may be present at 0.5% or 1% (e.g. paragraph 0066), and the instant specification defines “substantially free” as “less than about 2% of the identified ingredient” (e.g. Specification paragraph 0024). Regarding Claim 9, Rughani et al. do not teach the inclusion of any UV curable material (i.e. entre disclosure). Regarding Claim 11, Rughani et al. teach: 20-90 wt% of a solvent system comprising ethyl and butyl acetates (i.e. volatile acetates) (e.g. paragraph 0060); 1-25 wt% nitrocellulose (e.g. paragraph 0031); 1-20 wt% of one or more additional film-formers (e.g. paragraph 0047) including a silicone organic hybrid polymer comprising Crotonic Acid/Vinyl C8-12 Isoalkyl Esters/VA/Bis-Vinyldimethicone Crosspolymer (e.g. paragraph 0045); and 1-20 wt% of one or more additional film-formers (e.g. paragraph 0047) including an alkyd resin comprising phthalic anhydride/glycerol/glycidyl decanoate copolymer (e.g. paragraph 0046), all of which overlap with the claimed ranges. In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) (MPEP 2144.05.I). Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLE PLOURDE BABSON whose telephone number is (571)272-3055. The examiner can normally be reached M-Th 8-4:30; F 8-12:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NICOLE P BABSON/ Primary Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Sep 29, 2023
Application Filed
Jan 16, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599622
Compounds to Modulate Intestinal Absorption of Nutrients
2y 5m to grant Granted Apr 14, 2026
Patent 12600821
CROSSLINKED ORGANOSILICON RESIN, A METHOD FOR PRODUCING SAME, AND A COSMETIC
2y 5m to grant Granted Apr 14, 2026
Patent 12594354
COMPOSITIONS FOR VISUALIZATION OF CLEANING EFFICACY AND PRODUCT COVERAGE
2y 5m to grant Granted Apr 07, 2026
Patent 12594230
NOVEL SPHINGOLIPID CONTAINING SALICYLIC ACID DERIVATIVE AND COMPOSITION COMPRISING SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12582584
OXIDIZER AND ACID BASED SYSTEM AND REGIMEN FOR ENHANCING SKIN APPEARANCE
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
78%
With Interview (+31.8%)
3y 8m
Median Time to Grant
Low
PTA Risk
Based on 516 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month